This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $319,542 to Brigham & Women's Hospital Inc. to conduct research on "MODULATION OF EPIGENETIC REGULATORS CONTROLLING PATHOGENIC ASTROCYTES FOR THE TREATMENT OF MS." The award period runs from November 1, 2024 to October 31, 2026. As a subsidiary of Partners Healthcare System Incorporated, Brigham & Women's Hospital has extensive experience conducting federally-funded biomedical and clinical research across various medical specialties. This grant supports the hospital's efforts to advance scientific knowledge and improve treatment options for multiple sclerosis by studying how to modulate epigenetic regulators that influence pathogenic astrocytes.
Generated 3/4/25, 6:07 AM